Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers Squibb (BMY) and Bain Capital have announced the formation of a new independent biopharmaceutical company dedicated to developing innovative therapies for ...